Stap Tab

Dosage for Enterococcus Faecalis extracts is highly individualized and must be determined by an allergist or immunologist. Unlike standard pills, there is no 'one-size-fits-all' dose.

Diagnostic Testing Dosage

• Skin Prick Test (SPT): Usually performed using a concentration of 1:10 or 1:20 w/v in a glycerinated solution. A single drop is applied to the skin, and a sterile lancet is used to prick the area.
• Intradermal Test: If the SPT is negative but suspicion remains high, a more sensitive intradermal test may be used. This involves injecting 0.02 to 0.05 mL of a much more dilute extract (e.g., 1:1000 or 1:100 w/v) into the skin to create a small bleb.

Immunotherapy Dosage

Immunotherapy follows a 'Build-up Phase' and a 'Maintenance Phase.'

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution) administered once or twice weekly. The dose is gradually increased based on the patient's tolerance.
• Maintenance Phase: Once the 'top dose' is reached (often 0.5 mL of a 1:100 or 1:10 w/v dilution), the frequency of injections is decreased to once every 2 to 4 weeks.

Enterococcus Faecalis extracts may be used in children, but the procedure requires extreme caution.

• Age Considerations: Skin testing is generally avoided in infants under 6 months of age due to reduced skin reactivity.
• Dosing: The volume of extract used for testing is the same as in adults, but the number of simultaneous tests may be limited to prevent excessive discomfort or systemic reactions.
• Immunotherapy: Pediatric dosing for immunotherapy follows the same titration principles as adult dosing, but the healthcare provider will monitor the child more closely for signs of systemic distress.

Renal Impairment

No specific dosage adjustments are required for patients with kidney disease, as the systemic load of the extract is minimal. However, patients with severe renal failure may have altered skin reactivity (uremic pruritus), which can make skin test results difficult to interpret.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver disease. The metabolic clearance of these proteins does not rely significantly on hepatic CYP450 enzymes.

Elderly Patients

Elderly patients may have thinner skin and reduced mast cell density, which can lead to 'false negative' skin test results. Healthcare providers may use a positive control (histamine) to verify skin reactivity before testing with Enterococcus Faecalis.

This medication is never self-administered at home. It must be administered in a clinical setting equipped to handle emergency reactions.

• Administration: Injections are given subcutaneously (under the skin), usually in the back of the upper arm. The area should not be massaged after injection.
• Observation: Patients must remain in the doctor's office for at least 30 minutes after any injection. Most life-threatening reactions occur within this window.
• Storage: Vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should never be frozen, as freezing can denature the proteins and render the extract ineffective or dangerous.

In immunotherapy, consistency is vital. If a dose is missed:

• Less than 1 week late: The usual dose may often be given.
• 1-2 weeks late: The dose may need to be reduced to the previous level.
• More than 3 weeks late: The dose may need to be significantly reduced, or the build-up phase may need to be restarted to ensure safety.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level.

• Signs: Rapid onset of hives, swelling of the throat (angioedema), wheezing, shortness of breath, or a drop in blood pressure (fainting).
• Emergency Measures: Immediate administration of epinephrine (adrenaline) is the primary treatment. Other measures include oxygen, intravenous fluids, and antihistamines.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Enterococcus Faecalis extracts will experience some form of local reaction. These are generally considered expected pharmacological responses rather than 'adverse' events.

• Local Redness (Erythema): The area around the injection or test site may become red and warm. This typically appears within minutes and resolves within a few hours.
• Swelling (Wheal): A raised, itchy bump at the site of administration. For diagnostic tests, this is the measured outcome. For immunotherapy, a small wheal (less than the size of a quarter) is common.
• Itching (Pruritus): Intense itching at the site is very common. Patients are advised not to scratch, as this can worsen the swelling.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. This may be uncomfortable and can last for 24 to 48 hours. While not dangerous, it often requires a dosage adjustment for the next injection.
• Fatigue: Some patients report feeling unusually tired for several hours after receiving an immunotherapy injection.
• Headache: A mild, transient headache may occur following the administration of bacterial extracts.

• Generalized Urticaria (Hives): Hives appearing on parts of the body away from the injection site. This is a sign of a systemic allergic reaction.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).
• Persistent Granuloma: A small, hard knot under the skin at the injection site that may take weeks to resolve.

> Warning: Stop taking Enterococcus Faecalis and call your doctor immediately if you experience any of these symptoms of Anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or a persistent cough. This indicates the extract is causing airway constriction.
• Upper Airway Obstruction: A 'lump in the throat,' hoarseness, or difficulty swallowing, which suggests laryngeal edema (throat swelling).
• Cardiovascular Collapse: Dizziness, sudden paleness, rapid or weak pulse, or fainting. This is caused by a dangerous drop in blood pressure.
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after an injection.
• Angioedema: Significant swelling of the lips, tongue, or eyelids.

There are no known long-term 'toxic' effects of Enterococcus Faecalis extracts, as they are biological proteins that do not accumulate in tissues. However, the long-term immunological effect is the desired reduction in sensitivity. In rare cases, prolonged immunotherapy could theoretically contribute to the development of other autoimmune markers, though this is not supported by robust clinical evidence for bacterial extracts specifically.

While Enterococcus Faecalis extracts may not have an individual 'Black Box' for every manufacturer, the FDA requires a general Boxed Warning for all potent allergenic extracts regarding the risk of severe systemic reactions.

Summary of Warning:

• This product can cause severe, life-threatening systemic reactions, including anaphylaxis.
• It must only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and the management of anaphylaxis.
• Patients must be observed for at least 30 minutes in a facility equipped with emergency supplies (epinephrine, oxygen, airway management tools).
• Patients with unstable asthma are at a significantly higher risk for fatal reactions.

Report any unusual symptoms to your healthcare provider, even if they seem minor at first.

Enterococcus Faecalis allergenic extracts are biological products intended for use only by medical professionals. They are not 'vaccines' in the traditional sense of preventing infection; rather, they are tools for managing allergic hypersensitivity. The most critical safety consideration is the potential for an IgE-mediated systemic reaction.

No specific FDA black box warning exists solely for the 'Enterococcus Faecalis' strain, but it falls under the mandatory Boxed Warning for all Allergenic Extracts. This warning emphasizes that these products can cause anaphylaxis and should only be used in settings where emergency resuscitation is immediately available. It also warns that the risk of a severe reaction is increased in patients with symptomatic asthma or those taking certain medications like beta-blockers.

• Anaphylaxis Risk: This is the primary concern. A systemic reaction can occur even if the patient has tolerated previous doses perfectly. There is no way to predict with 100% certainty who will react.
• Asthma Status: Patients with uncontrolled or severe asthma should not receive Enterococcus Faecalis injections. If a patient is experiencing an asthma flare-up on the day of their injection, the dose must be postponed.
• Acute Illness: Injections should be avoided if the patient has a fever or an active infection, as this can lower the threshold for a systemic allergic reaction.
• Skin Conditions: Patients with widespread eczema or dermatitis may have unreliable skin test results. Testing should be performed on clear areas of skin.

Patients undergoing immunotherapy with Enterococcus Faecalis require ongoing monitoring:

• Wait Time: A strict 30-minute post-injection waiting period.
• Peak Flow: For asthmatic patients, a peak flow meter may be used before and after the injection to ensure lung function is stable.
• Symptom Review: At each visit, the provider will ask about any 'late-phase' reactions (swelling that occurred hours after the last dose).
• Lab Tests: While routine blood work isn't usually required for the extract itself, doctors may monitor IgE and IgG4 levels to track the progress of the therapy.

Most patients can drive after the 30-minute waiting period. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive and must be monitored in an emergency setting.

Alcohol should be avoided on the day of an injection. Alcohol causes vasodilation (opening of blood vessels), which can increase the rate at which the allergen enters the bloodstream, potentially increasing the risk of a systemic reaction.

Immunotherapy is typically a 3-to-5-year commitment. Stopping suddenly will not cause 'withdrawal' in the traditional sense, but the allergic sensitivity will likely return to its baseline level. If a patient experiences a life-threatening reaction, the therapy is usually discontinued permanently.

> Important: Discuss all your medical conditions with your healthcare provider before starting Enterococcus Faecalis.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are strictly contraindicated or used with extreme caution during allergy testing and immunotherapy. Clinical Consequence: Beta-blockers can make a systemic allergic reaction (anaphylaxis) much more severe and, more importantly, they can make the reaction resistant to epinephrine. If a patient on a beta-blocker has a reaction, the standard life-saving treatment may not work.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These blood pressure medications may increase the risk of more severe systemic reactions or angioedema (deep tissue swelling) during immunotherapy.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the body's ability to process the medications used to treat a reaction (like epinephrine), potentially leading to a hypertensive crisis.

• Antihistamines (e.g., Loratadine, Cetirizine, Diphenhydramine):
• Mechanism: These drugs block the H1 receptors that cause the 'wheal and flare.'
• Consequence: They will cause a false-negative result on a skin test.
• Management: Patients must stop taking most antihistamines for 3 to 7 days before diagnostic testing. However, they are often continued during immunotherapy to reduce minor side effects.
• Tricyclic Antidepressants (e.g., Amitriptyline): These have potent antihistamine properties and can similarly interfere with diagnostic skin testing results for up to two weeks.

• Heavy Meals: It is generally advised not to eat a very heavy or spicy meal immediately before or after an injection, as this can increase core body temperature and blood flow, potentially accelerating allergen absorption.
• Alcohol: As noted, alcohol can increase the risk of a systemic reaction by causing vasodilation.

• High-Dose Vitamin C: Some evidence suggests very high doses of Vitamin C may have a mild antihistamine effect, which could theoretically interfere with skin test accuracy.
• St. John's Wort: May interact with medications used in emergency settings, though the risk is considered low.

• Skin Tests: The extract itself is the 'test.' Any drug that suppresses the immune system or the histamine response will interfere with the results.
• Total IgE: Immunotherapy may cause a transient rise in total serum IgE before it eventually stabilizes or decreases.

For each major interaction, the primary strategy is prevention. Always provide a full list of medications to your allergist.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Conditions where Enterococcus Faecalis extracts must NEVER be used include:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted values are at an unacceptably high risk of fatal bronchospasm during a reaction.
2. 2Recent Myocardial Infarction (Heart Attack): The stress of a potential systemic reaction and the subsequent need for epinephrine could be fatal in a patient with an unstable heart.
3. 3Beta-Blocker Therapy: Due to the risk of epinephrine-resistant anaphylaxis (as detailed in the Interactions section).
4. 4Previous Near-Fatal Reaction: If a patient has already had a life-threatening reaction to Enterococcus Faecalis, the risk of continuing therapy usually outweighs any potential benefit.

These conditions require a careful risk-benefit analysis by the specialist:

• Pregnancy: While immunotherapy is generally not started during pregnancy, it may be continued if the patient is already on a stable maintenance dose. Testing is usually deferred.
• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with bacterial extracts could worsen conditions like Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis.
• Malignancy: Patients with active cancer may have altered immune responses, making immunotherapy less effective or more unpredictable.
• Young Children: Children under age 5 may be unable to communicate the early symptoms of a systemic reaction, increasing the danger.

Patients allergic to Enterococcus Faecalis may show cross-reactivity with other Enterococcaceae or Streptococcaceae species. If you have had a severe reaction to a Streptococcus extract, you must inform your doctor, as the proteins are structurally similar and may cause a cross-allergic reaction.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Enterococcus Faecalis.

• Risk Summary: Enterococcus Faecalis extracts are generally classified as Pregnancy Category C. This means there are no adequate, well-controlled studies in pregnant women.
• Clinical Considerations: Diagnostic skin testing is typically avoided during pregnancy because a systemic reaction (and the resulting drop in blood pressure or the need for epinephrine) could cause fetal hypoxia (lack of oxygen to the baby).
• Immunotherapy: Most allergists will not start a new course of immunotherapy during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the therapy is often continued, as the risk of a reaction is low at that stage.

• Passage into Milk: It is highly unlikely that the proteins in the extract pass into breast milk in any significant or bioactive form.
• Safety: Breastfeeding is not considered a contraindication for receiving Enterococcus Faecalis injections. There are no known adverse effects on the nursing infant.

• Approved Age: While there is no strict lower age limit, it is rarely used in children under 5 years old.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development.
• Special Considerations: The primary challenge in pediatrics is the child's ability to report early symptoms of anaphylaxis (e.g., an 'itchy throat' or 'funny feeling').

• Pharmacokinetic Changes: Older adults may have reduced skin reactivity, leading to more 'false negatives' in testing.
• Polypharmacy: The elderly are more likely to be on beta-blockers or ACE inhibitors, which increases the risk profile of the extract.
• Cardiovascular Health: The presence of underlying heart disease in geriatric patients makes the management of a systemic reaction more complex.

No dosage adjustments are required. The proteins are degraded locally and systemically by proteases. However, severe uremia (buildup of toxins in the blood due to kidney failure) can suppress skin test reactivity.

No adjustments are necessary. The liver's metabolic capacity does not significantly impact the safety or efficacy of subcutaneous allergenic extracts.

> Important: Special populations require individualized medical assessment to ensure the benefits of testing or therapy outweigh the risks.

Enterococcus Faecalis extract acts as an exogenous antigen. In sensitized individuals, the primary molecular target is the high-affinity IgE receptor (FcεRI) located on the surface of mast cells and basophils.

1. 1Antigen Binding: The bacterial proteins (antigens) bind to the Fab portion of the IgE antibodies already attached to the FcεRI receptors.
2. 2Cross-linking: Multiple IgE molecules are pulled together (cross-linked) by the multivalent bacterial antigens.
3. 3Signal Transduction: This cross-linking triggers an intracellular signaling cascade involving tyrosine kinases (like Syk).
4. 4Mediator Release: This results in the rapid exocytosis of pre-formed mediators (histamine, heparin) and the de novo synthesis of leukotrienes and cytokines.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations of the extract produce larger wheals, up to a saturation point.
• Onset of Effect: In skin testing, the 'immediate' reaction peaks at 15-20 minutes. A 'late-phase' reaction may occur 4 to 12 hours later, characterized by more diffuse swelling and induration.
• Duration of Effect: The diagnostic reaction usually fades within 24 hours. The therapeutic effect of immunotherapy can last for years after the treatment is completed, a phenomenon known as 'immunological memory.'

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous) / Negligible (Skin Prick) |

| Protein Binding | N/A (Biological Extract) |

| Half-life | Minutes to hours (for individual proteins) |

| Tmax | 15-20 minutes (for local reaction) |

| Metabolism | Proteolysis by tissue and plasma enzymes |

| Excretion | Minimal renal excretion of peptide fragments |

• Composition: A complex mixture of water-soluble proteins, glycoproteins, and polysaccharides derived from Enterococcus faecalis cells.
• Solubility: Highly soluble in aqueous solutions (saline, phosphate buffers).
• Molecular Weight: Ranges from <10 kDa to >100 kDa for various bacterial antigens.

Enterococcus Faecalis is classified as a Non-Standardized Allergenic Extract. It is grouped with other microbial extracts used in 'Allergy of Infection' theories, although its modern use is strictly focused on IgE-mediated hypersensitivity. Within the EPC (Established Pharmacologic Class) system, it is categorized as a Non-Standardized Food Allergenic Extract [EPC], though it is biologically a bacterial extract.